MDM2 SNP309 and cancer risk: a combined analysis.

A paper by Bond et al. reported that a single-nucleotide polymorphism (SNP) in the intronic promoter region of the mouse double minute 2 (MDM2) gene (called SNP309) can significantly change the expression of MDM2 and thereby suppress the p53 pathway. Furthermore, it was shown that SNP309 accelerates tumor formation in Li-Fraumeni patients. This initial report aroused the attention of many researchers, which investigated the role of SNP309 for the risk and the onset of cancer in different tissues. To provide a more robust estimate of the effect of this polymorphism on cancer risk, we combined the available genotype data for breast, colorectal and lung cancers. For breast cancer, we combined the data from 11 studies including 5737 cases and 6703 controls. For colorectal cancer, we combined the data from five studies with 1620 cases and 886 controls. For lung cancer, we performed a fixed-effect meta-analysis from seven studies including 4276 cases and 5318 controls. Our results suggest that the SNP309 variant does not have an impact on the risk of breast [odds ratio (OR) = 0.97, 95% confidence interval (CI) = 0.87-1.08] or colorectal cancers (OR = 0.97, 95% CI = 0.76-1.25). However, the combined estimate of the ORs for lung cancer revealed an increased risk for GG versus TT (OR = 1.27, 95% CI = 1.12-1.44). The data show that SNP309 alone has little or no effect on the risk of common cancers, but it might modify the time of tumor onset and prognosis.

[1]  K. Hemminki,et al.  No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin , 2007, The British journal of dermatology.

[2]  J. Klijn,et al.  MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling , 2007, Breast Cancer Research and Treatment.

[3]  H. Iwata,et al.  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients , 2007, Breast Cancer Research.

[4]  F. He,et al.  MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007, Clinical Cancer Research.

[5]  Gustavo Stolovitzky,et al.  A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. , 2007, Cancer research.

[6]  Carl W. Miller,et al.  Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. , 2007, Gynecologic oncology.

[7]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[8]  Dong Sun Kim,et al.  Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer , 2007, Molecular carcinogenesis.

[9]  R. Scott,et al.  MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients , 2007, International journal of cancer.

[10]  David J. Hunter,et al.  The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.

[11]  Rochelle L. Garcia,et al.  Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. , 2006, Gynecologic oncology.

[12]  I. Yulug,et al.  Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. , 2006, Anticancer research.

[13]  M. Spitz,et al.  MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. , 2006, Carcinogenesis.

[14]  J. Park,et al.  MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. , 2006, Lung cancer.

[15]  Y. Hirooka,et al.  MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Neuberg,et al.  Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[17]  T. Ozcelik,et al.  MDM2 T309G polymorphism is associated with bladder cancer. , 2006, Anticancer research.

[18]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[19]  Hongbing Shen,et al.  Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. , 2006, Cancer letters.

[20]  N. Kato,et al.  MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006, Clinical Cancer Research.

[21]  E. Bowman,et al.  MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[23]  Hiroyuki Yamamoto,et al.  Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells , 2006, Journal of Medical Genetics.

[24]  A. Levine,et al.  MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.

[25]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[26]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[27]  D. Eccles,et al.  Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers , 2006, BMC Cancer.

[28]  Hongbing Shen,et al.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population , 2006, International journal of cancer.

[29]  R. Bertorelle,et al.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. , 2006, Journal of the National Cancer Institute.

[30]  P. Bugert,et al.  The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. , 2006, Cancer research.

[31]  R. Millikan,et al.  No Association Between the MDM2 −309 T/G Promoter Polymorphism and Breast Cancer in African-Americans or Whites , 2006, Cancer Epidemiology Biomarkers & Prevention.

[32]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[33]  A. Levine,et al.  Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Tomlinson,et al.  MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia , 2005, Leukemia.

[35]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[36]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[37]  Sandya Liyanarachchi,et al.  p53 Codon 72 and MDM2 SNP309 Polymorphisms and Age of Colorectal Cancer Onset in Lynch Syndrome , 2005, Clinical Cancer Research.

[38]  L. Aaltonen,et al.  The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.

[39]  A. Levine,et al.  A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.

[40]  A. Levine,et al.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.

[41]  Ruiwen Zhang,et al.  p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.

[42]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[43]  D. Easton,et al.  EMGM Abstracts , 2003, Genetic epidemiology.

[44]  J. Peto,et al.  The future of association studies of common cancers , 2003, Human Genetics.

[45]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[46]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[47]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[48]  M. Oren,et al.  A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.

[49]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[50]  Haoyang,et al.  MDM 2 Promoter SNP 309 Is Associated with Risk of Occurrence and Advanced Lymph NodeMetastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007 .

[51]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[52]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM 2 Gene Disrupts the Oscillation of p 53 and MDM 2 Levels in Cells , 2007 .

[53]  P. Bugert,et al.  The Single Nucleotide Polymorphism IVS 1 + 309 in Mouse Double Minute 2 Does Not Affect Risk of Familial Breast Cancer , 2006 .

[54]  N. Kato,et al.  MDM 2 Promoter SNP 309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006 .

[55]  L. Aaltonen,et al.  The MDM 2 promoter polymorphism SNP 309 T R G and the risk of uterine leiomyosarcoma , colorectal cancer , and squamous cell carcinoma of the head and neck , 2005 .

[56]  W. Tan,et al.  The Role of P 53 and MDM 2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma , 2005 .